Single-dose pharmacokinetics of methylphenidate in CYP2D6 extensive and poor metabolizers

C. Lindsay DeVane; John S. Markowitz; Stanley W. Carson; David W. Boulton; Harry S. Gill; Ziah Nahas; S. Craig Risch

doi:10.1097/00004714-200006000-00009

Single-dose pharmacokinetics of methylphenidate in CYP2D6 extensive and poor metabolizers

C. Lindsay DeVane, John S. Markowitz, Stanley W. Carson, David W. Boulton, Harry S. Gill, Ziah Nahas, S. Craig Risch

Psychiatry & Behavioral Sciences

Research output: Contribution to journal › Article › peer-review

30 Scopus citations

Abstract

Six adults phenotyped as either extensive (N = 4) or poor (N = 2) metabolizers for cytochrome P450 (CYP) 2D6 were given a 10-mg oral dose of methylphenidate (MPH) on two separate occasions with and without quinidine, a potent CYP2D6 inhibitor. Quinidine had no significant effect on the pharmacokinetics of either MPH or ritalinic acid, its major metabolite, in either group of CYP2D6 metabolizers. These data suggest a lack of involvement of CYP2D6 in the metabolism of MPH. Drugs that are inhibitors of CYP2D6 when taken concurrently with MPH should not affect its plasma concentration.

Original language	English (US)
Pages (from-to)	347-349
Number of pages	3
Journal	Journal of Clinical Psychopharmacology
Volume	20
Issue number	3
DOIs	https://doi.org/10.1097/00004714-200006000-00009
State	Published - Jun 1 2000

Access

10.1097/00004714-200006000-00009

Fingerprint Dive into the research topics of 'Single-dose pharmacokinetics of methylphenidate in CYP2D6 extensive and poor metabolizers'. Together they form a unique fingerprint.

Cite this

@article{c594ae570f76462792fdcf4fe80d2987,

title = "Single-dose pharmacokinetics of methylphenidate in CYP2D6 extensive and poor metabolizers",

abstract = "Six adults phenotyped as either extensive (N = 4) or poor (N = 2) metabolizers for cytochrome P450 (CYP) 2D6 were given a 10-mg oral dose of methylphenidate (MPH) on two separate occasions with and without quinidine, a potent CYP2D6 inhibitor. Quinidine had no significant effect on the pharmacokinetics of either MPH or ritalinic acid, its major metabolite, in either group of CYP2D6 metabolizers. These data suggest a lack of involvement of CYP2D6 in the metabolism of MPH. Drugs that are inhibitors of CYP2D6 when taken concurrently with MPH should not affect its plasma concentration.",

author = "DeVane, {C. Lindsay} and Markowitz, {John S.} and Carson, {Stanley W.} and Boulton, {David W.} and Gill, {Harry S.} and Ziah Nahas and Risch, {S. Craig}",

year = "2000",

month = jun,

day = "1",

doi = "10.1097/00004714-200006000-00009",

language = "English (US)",

volume = "20",

pages = "347--349",

journal = "Journal of Clinical Psychopharmacology",

issn = "0271-0749",

publisher = "Lippincott Williams and Wilkins",

number = "3",

}

TY - JOUR

T1 - Single-dose pharmacokinetics of methylphenidate in CYP2D6 extensive and poor metabolizers

AU - DeVane, C. Lindsay

AU - Markowitz, John S.

AU - Carson, Stanley W.

AU - Boulton, David W.

AU - Gill, Harry S.

AU - Nahas, Ziah

AU - Risch, S. Craig

PY - 2000/6/1

Y1 - 2000/6/1

N2 - Six adults phenotyped as either extensive (N = 4) or poor (N = 2) metabolizers for cytochrome P450 (CYP) 2D6 were given a 10-mg oral dose of methylphenidate (MPH) on two separate occasions with and without quinidine, a potent CYP2D6 inhibitor. Quinidine had no significant effect on the pharmacokinetics of either MPH or ritalinic acid, its major metabolite, in either group of CYP2D6 metabolizers. These data suggest a lack of involvement of CYP2D6 in the metabolism of MPH. Drugs that are inhibitors of CYP2D6 when taken concurrently with MPH should not affect its plasma concentration.

AB - Six adults phenotyped as either extensive (N = 4) or poor (N = 2) metabolizers for cytochrome P450 (CYP) 2D6 were given a 10-mg oral dose of methylphenidate (MPH) on two separate occasions with and without quinidine, a potent CYP2D6 inhibitor. Quinidine had no significant effect on the pharmacokinetics of either MPH or ritalinic acid, its major metabolite, in either group of CYP2D6 metabolizers. These data suggest a lack of involvement of CYP2D6 in the metabolism of MPH. Drugs that are inhibitors of CYP2D6 when taken concurrently with MPH should not affect its plasma concentration.

UR - http://www.scopus.com/inward/record.url?scp=0034081601&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034081601&partnerID=8YFLogxK

U2 - 10.1097/00004714-200006000-00009

DO - 10.1097/00004714-200006000-00009

M3 - Article

C2 - 10831022

AN - SCOPUS:0034081601

VL - 20

SP - 347

EP - 349

JO - Journal of Clinical Psychopharmacology

JF - Journal of Clinical Psychopharmacology

SN - 0271-0749

IS - 3

ER -